Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

Table 3 Effect of ABCB1 single nucleotide polymorphism on tacrolimus pharmacokinetics

Ref.	Study population	Transplant type/analysis of recipients, donors or both	Findings
Provenzani et al[91]	32 Caucasian	Liver recipients and donors	No influence of 3435C>T and 2677G>T SNPs on tacrolimus dose requirements
Cho et al[84]	70 Korean	Kidney recipients	No association between ABCB1 genotype and tacrolimus dose requirements
Shi et al[66]	216 Chinese	Liver recipients	No association between any ABCB1 SNPs and tacrolimus dose requirements or blood trough levels
Jun et al[98]	568 Korean	Kidney and liver recipients (n = 506), and liver donors (n = 62)	No correlation between ABCB1 genotype and tacrolimus dose-adjusted blood trough levels
Gervasini et al[33]	103 Spanish	Kidney recipients	None of the ABCB1 polymorphisms were associated with changes in dose-adjusted blood trough levels and in dose requirementsNo association between ABCB1 genotype and tacrolimus-induced toxicity
Kuypers et al[104]	304 Belgian	Kidney recipients	No significant impact of ABCB1 genotype on tacrolimus exposure parameters or dosing requirements
Provenzani et al[92]	101 Caucasian	Kidney (n = 50) and liver (n = 51, recipients and donors)	No ABCB1 influence on dosing in liver transplant patientsThose patients receiving kidney transplant carrying the 2677T/A allele required significantly higher doses than those patients with the wild type allele
Goto et al[63]	181 Japanese	Liver recipients and donors	In the first week after transplantation, the recipients with wild type ABCB1 allele had lower tacrolimus dose-adjusted blood trough levelsNo difference observed after 2 wk
Herrero et al[43]	71 Spanish	Kidney recipients	Patients with wild type ABCB1 alleles had more stable tacrolimus concentrations within the therapeutic range during the first 3 moOn the contrary, patients carrying the polymorphic ABCB1 alleles showed a mean increase in tacrolimus blood concentration of more than 60%
Wei-Lin et al[88]	50 Chinese	Liver recipients and donors	Recipients with the wild type ABCB1-3435CC allele had significantly higher tacrolimus dose requirements than those with C3435T at 1 and 2 wk and 1 mo after transplantation
López-Montenegro Soria et al[97]	35 Spanish	Kidney recipients	Wild type ABCB1 3435CC patients had 40% lower concentration/dose ratios than those patients with variant alleles
Elens et al[99]	150 Belgian	Liver donors	ABCB1 genetic polymorphisms significantly influence tacrolimus hepatic concentrations, but have no effect on tacrolimus blood levelsPatients with ABCB1 1236C>T polymorphism showed significantly better liver functions and lower Banff scores with respect to patients with the wild-type allele